Inbiomotion: Predicting bone metastasis

Startup

ABOUT INBIOMOTION

      
Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2010 with the goal of developing biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company is a spin out of the IRB Barcelona and ICREA research institutions and was founded by Dr. Roger Gomis.

Our activities are focused on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. The exquisite selectivity of our lead biomarker provides the grounds for the development of companion diagnostics – selecting patients that will benefit from the preventive use of anti-bone metastatic drugs, and making a step forward in the clinical standard of care using personalized medicine.
    
Organization founded in Spain.

TEAM CREW

SECTORS - INDUSTRY

PROFILE STRENGTH

This profile looks great, do you want to share it with the world?
BEGINNER
ADVANCED
REAL PRO

This website uses cookies to allow us to see how the site is used. If you continue to use this site we will assume that you are happy with this. If you want to use the site without cookies or would like to know more, you can do that. here .